OxindoleCAS# 59-48-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 59-48-3 | SDF | Download SDF |
PubChem ID | 321710 | Appearance | Powder |
Formula | C8H7NO | M.Wt | 133.2 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Synonyms | Indolin-2-one;2-Oxindole;2-Indolinone | ||
Solubility | DMSO : 100 mg/mL (751.03 mM; Need ultrasonic) | ||
Chemical Name | 1,3-dihydroindol-2-one | ||
SMILES | C1C2=CC=CC=C2NC1=O | ||
Standard InChIKey | JYGFTBXVXVMTGB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H7NO/c10-8-5-6-3-1-2-4-7(6)9-8/h1-4H,5H2,(H,9,10) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development. |
Oxindole Dilution Calculator
Oxindole Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 7.5075 mL | 37.5375 mL | 75.0751 mL | 150.1502 mL | 187.6877 mL |
5 mM | 1.5015 mL | 7.5075 mL | 15.015 mL | 30.03 mL | 37.5375 mL |
10 mM | 0.7508 mL | 3.7538 mL | 7.5075 mL | 15.015 mL | 18.7688 mL |
50 mM | 0.1502 mL | 0.7508 mL | 1.5015 mL | 3.003 mL | 3.7538 mL |
100 mM | 0.0751 mL | 0.3754 mL | 0.7508 mL | 1.5015 mL | 1.8769 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Procaine
Catalog No.:BCC5210
CAS No.:59-46-1
- Thiamine chloride
Catalog No.:BCN8344
CAS No.:59-43-8
- Sulfaquinoxaline
Catalog No.:BCC9158
CAS No.:59-40-5
- Mepyramine maleate
Catalog No.:BCC6740
CAS No.:59-33-6
- Folic acid
Catalog No.:BCN5375
CAS No.:59-30-3
- D-Galactose
Catalog No.:BCN8528
CAS No.:59-23-4
- 5-BrdU
Catalog No.:BCC5293
CAS No.:59-14-3
- Ethopabate
Catalog No.:BCC8964
CAS No.:59-06-3
- Methotrexate
Catalog No.:BCC2301
CAS No.:59-05-2
- DL-alpha-Tocopherol
Catalog No.:BCN2200
CAS No.:59-02-9
- Xanthurenic acid
Catalog No.:BCC7866
CAS No.:59-00-7
- Bestatin
Catalog No.:BCC1221
CAS No.:58970-76-6
- DL-Methionine
Catalog No.:BCC8318
CAS No.:59-51-8
- Nicotinic acid
Catalog No.:BCN8328
CAS No.:59-67-6
- Nitrofurazone
Catalog No.:BCC3825
CAS No.:59-87-0
- Levodopa
Catalog No.:BCN1098
CAS No.:59-92-7
- Tolazoline HCl
Catalog No.:BCC4321
CAS No.:59-97-2
- Betaine hydrochloride
Catalog No.:BCN6304
CAS No.:590-46-5
- Bethanechol chloride
Catalog No.:BCC4566
CAS No.:590-63-6
- alpha-Endorphin
Catalog No.:BCC1010
CAS No.:59004-96-5
- 8-Hydroxyhyperforin 8,1-hemiacetal
Catalog No.:BCN4091
CAS No.:59014-02-7
- Atropine sulfate monohydrate
Catalog No.:BCC3728
CAS No.:5908-99-6
- Dehydrotoxicarol
Catalog No.:BCN3991
CAS No.:59086-93-0
- Albaspidin AP
Catalog No.:BCN2398
CAS No.:59092-91-0
Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.[Pubmed:25456085]
Bioorg Med Chem. 2014 Dec 15;22(24):6953-60.
Given that receptor tyrosine kinases (RTKs) have emerged as key regulators of all aspects of cancer development, including proliferation, invasion, angiogenesis and metastasis, the RTK family represents an important therapeutic target for anti-cancer drug development. Oxindole structure has been used in RTK inhibitors such as SU4984 and intedanib. In this study, two series of new heterocyclic compounds containing Oxindole scaffold have been designed and synthesized, and their inhibitory activity against the proliferation of nine cancer cell lines has been evaluated. Among them, compounds 9a and 9b displayed the strongest anti-proliferative activity with the IC50s below 10muM. Flow cytometric analysis showed that the compounds 9a and 9b dose-dependently arrested the cell cycle at G0/G1 phase. Although the leading compounds SU4984 and intedanib targets FGFR1, the kinase activity test revealed that these compounds only showed slight inhibitory activity on FGFR1 kinase. Further enzymatic test aided by molecular docking simulation in the ATP-binding site demonstrated that 9a and 9b are potent inhibitors of c-Kit kinase. These compounds are worthy of further evaluation as anticancer agents.
Synthesis of novel derivatives of oxindole, their urease inhibition and molecular docking studies.[Pubmed:26077497]
Bioorg Med Chem Lett. 2015 Aug 15;25(16):3285-9.
We synthesized a series of novel 5-24 derivatives of Oxindole. The synthesis started from 5-chloroOxindole, which was condensed with methyl 4-carboxybezoate and result in the formation of benzolyester derivatives of Oxindole which was then treated with hydrazine hydrate. The Oxindole benzoylhydrazide was treated with aryl acetophenones and aldehydes to get target compounds 5-24. The synthesized compounds were evaluated for urease inhibition; the compound 5 (IC50 = 13.00 +/- 0.35 muM) and 11 (IC50 = 19.20 +/- 0.50 muM) showed potent activity as compared to the standard drug thiourea (IC50 = 21.00 +/- 0.01 muM). Other compounds showed moderate to weak activity. All synthetic compounds were characterized by different spectroscopic techniques including (1)H NMR, (13)C NMR, IR and EI MS. The molecular interactions of the active compounds within the binding site of urease enzyme were studied through molecular docking simulations.